Roberto Formisano, Process Transfer Senior Manager at AGC Biologics, discusses the challenges of technology transfer in an interview. He speaks about the complexities of transferring technology from development to GMP manufacturing as well as from a customer to a contract development and manufacturing organization (CDMO).
Roberto highlights the critical timelines that pose significant challenges in technology transfer. He explains that balancing the number of batches required for manufacturing is crucial to obtaining sufficient and scientifically valid data within these timeframes.
Roberto also shares his insights on the technology and manufacturing trends and priorities he foresees for the cell and gene therapy industry in 2024. During his conversation with EPR editor Caroline Peachey at Terrapin’s Advanced Therapies conference on 19 March, Roberto delves into the intricacies of technology transfer and its implications for the industry.
In summary, Roberto Formisano provides valuable insights into the challenges of technology transfer in the cell and gene therapy industry. His discussion of critical timelines, balancing batch numbers, and future trends offers valuable information for those interested in this rapidly evolving field.
